Results 181 to 190 of about 7,268 (227)

Secondary Interaction Between MDMX and p53 Core Domain Inhibits p53 DNA Binding

Proceedings of the National Academy of Sciences of the United States of America, 2016
The MDMX oncoprotein is an important regulator of tumor suppressor p53 activity during embryonic development. Despite sequence homology to the ubiquitin E3 ligase MDM2, MDMX depletion activates p53 without significant increase in p53 level, implicating a
Jiandong Chen, Ming Gao, Wade Borcherds
exaly   +2 more sources

The Roles of MDM2 and MDMX in Cancer [PDF]

Annual Review of Pathology: Mechanisms of Disease, 2016
For more than 25 years, MDM2 and its homolog MDMX (also known as MDM4) have been shown to exert oncogenic activity. These two proteins are best understood as negative regulators of the p53 tumor suppressor, although they may have additional p53-independent roles.
Orit, Karni-Schmidt, Maria, Lokshin, Carol, Prives   +2 more
exaly   +3 more sources

MDMX Contains an Autoinhibitory Sequence Element [PDF]

Proceedings of the National Academy of Sciences of the United States of America, 2013
Significance The protein MDMX is an important negative regulator of the tumor suppressor p53 in normal cells and can become a powerful oncogene. Previous studies on isolated protein fragments established that the N-terminal domain of MDMX binds tightly to the N-terminal domain of p53 and inhibits it.
Michal Bista, Alan R Fersht
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Modification of MDMX by sumoylation

Biochemical and Biophysical Research Communications, 2005
MDMX is a homolog of MDM2 and is critical for regulating p53 function during mouse development. MDMX level is regulated by MDM2-mediated poly-ubiquitination, which results in its accelerated degradation after DNA damage or expression of ARF. In this report, we demonstrate that MDMX can be modified by conjugation to SUMO-1 both in vivo and in vitro.
Yu, Pan, Jiandong, Chen
openaire   +2 more sources

Targeting MDM2 and MDMX in Retinoblastoma

Current Cancer Drug Targets, 2007
Retinoblastoma is the third most common form of cancer in infants, and metastatic retinoblastoma is lethal in approximately 90% of cases. Early detection and aggressive therapy has resulted in a 95% probability of survival for retinoblastoma patients in the United States.
Nikia A, Laurie, Chie-Schin, Shih, Chie, Schin-Shih, Michael A, Dyer   +3 more
openaire   +2 more sources

Structure-based discovery of novel α-aminoketone derivatives as dual p53-MDM2/MDMX inhibitors for the treatment of cancer.

European journal of medicinal chemistry, 2023
The function of the p53 protein is impaired by the overexpression of its negative regulator murine double minute 2 protein (MDM2) and homologous protein MDMX.
Hui Luo, Dongjuan Si, Xin Sun, Mengyun Wang, Yaoyao Yang, Bo-wen Wang, H. Wen, Wei Li, Jian Liu   +8 more
semanticscholar   +1 more source

MDMX drives pre-leukaemia progression

Nature Reviews Cancer, 2021
Ueda et al. report that overexpression of MDMX in pre-leukaemic stem cells provides these cells with a competitive advantage and promotes the progression of various pre-leukaemic conditions to acute myeloid leukaemia in several mouse models.
openaire   +2 more sources

The role of miRNAs in MDMX‐p53 interplay

Journal of Evidence-Based Medicine, 2021
AbstractMicroRNAs (miRNAs) are endogenous noncoding RNAs of 19‐24 nucleotides in length and are tightly related to tumorigenesis and progression. Recent studies have demonstrated that the tumor suppressor p53 and its negative controller MDMX are regulated by miRNAs in different ways.
Dehua Yu, Zhiyuan Xu, Xiangdong Cheng, Jiangjiang Qin   +3 more
openaire   +2 more sources

64Cu-Labeled Stapled Peptide-Based Radiopharmaceuticals Targeting MDM2/MDMX for Pan-p53 Tumors.

Journal of Medicinal Chemistry
The development of ideal peptide-based radiopharmaceuticals faces critical bottlenecks, primarily due to limited cellular internalization and insufficient deep tissue penetration of peptide carriers.
Hao Tian, Quan Zuo, Si-Qi Zhang, Hong-Yi Huang, Dengfu Wu, Zihan Huang, Xiang-Ding Liu, Lin Xie, Yi-Ding Zhang, Hai-Long Zhang, Yekuan Shi, Su-Ping Li, Ming-Rong Zhang, Rui Wang, Kuan Hu   +14 more
semanticscholar   +1 more source

Mdm2 and MdmX: Partners in p53 Destruction

Cancer Research, 2021
Abstract Mdm2 and MdmX are two closely related proteins that have been well-characterized as negative regulators of the tumor suppressor p53. Their interplay and especially respective roles in ubiquitination and subsequent degradation of p53 have lacked clarity. Yang and colleagues now demonstrate an obligate role for MdmX in recruitment
openaire   +2 more sources